That means the effects seen in studies using injections or topical applications dont always translate directly to oral forms
The available evidence consists primarily of animal studies and limited early-phase human trials, with no published phase III clinical trial data demonstrating efficacy in inflammatory bowel disease (IBD).[1][2] The literature describes BPC-157 as a stable gastric pentadecapeptide that was tested in phase II clinical trials for inflammatory bowel disease (referenced as PL 14736), with reports indicating it was "safe" and had "no side effects." However, a 2025 review emphasizes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."[1][3][2] The preclinical evidence is extensive but limited to animal models
The exact amount depends on your prescribed concentration and how many units you intend to inject per dose
It can lead you to extreme pain in the heel
Environmental Science and Pollution Research International, 24(28): 2215222157 Zhou Z, Qiao W, Xing C, Shen X, Hu D, Wang L (2014)
Clinical studies also support the effectiveness of peptides for sleep in humans
